asa statement on glp 1 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations the peri-procedural use of GLP-1/GIP receptor agonists Perioperative Management of GLP-1 Receptor

Nov 30 2016;14(4):330-337

Longterm use of GLP1 receptor agonists is generally welltolerated, but clinicians should monitor for gastrointestinal side effects, rare risks like pancreatitis, and individual response

C.LogsdonA

Control of tumor-associated macrophage responses by nutrient acquisition and metabolism

Key ingredient Glutathione (2%) regulates melanin production to visibly reduce dark spots and even skin tone , paired with NMN (Nicotinamide Mononucleotide) to activate cellular energy and restore skin vitality

During this phase, injection frequency is higher to build systemic levels of the peptide and begin the actin regulation and angiogenesis responses